Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Completed · Phase 1/Phase 2
Conditions studied: Lung Neoplasms
In brief
This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer. This treatment is for patients that have not received any prior chemotherapy treatment for lung cancer. The primary goal is to find out if the tumor gets smaller or disappears with this treatment.
Key facts
- Study ID
- NCT00071136
- Run by
- Eli Lilly and Company
- People needed
- 48
- Starts
- 2003-12-01
- Expected to finish
- 2006-08-01
- Last updated by the study team
- 2007-01-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have a diagnosis of advanced stage non-small cell lung cancer.
- Are able to be active at home and/or work.
- Have not received chemotherapy for this cancer disease.
- Have good organ function (for example, most blood work is normal).
- Have completed any prior radiation treatment at least 4 weeks ago.
You may not qualify if…
- Have been treated with an investigational/research drug within the last month.
- Have cancer that has spread to the brain and is causing symptoms.
- Have an active infection or other serious medical condition.
- Have a second cancer in addition to non-small cell lung cancer.
- Can not stop taking aspirin or other anti-inflammatory agents for 5-8 days.
Where it is running
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician. — Fort Myers, Florida, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician. — Marshfield, Minnesota, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician. — Minneapolis, Minnesota, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician. — Rochester, New York, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician. — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.